Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.

MLA

He, Shui-Qing, et al. “Establishing M1 Subdivision for de Novo Nasopharyngeal Carcinoma Patients Receiving Immuno-Chemotherapy: A Multicenter, Retrospective Cohort Study.” Oral Oncology, vol. 159, Dec. 2024, p. 107074. EBSCOhost, https://doi.org/10.1016/j.oraloncology.2024.107074.

APA

He, S.-Q., Liu, G.-Y., Yu, Y.-H., Wang, L., Zhang, G.-Y., Peng, D.-S., Bei, W.-X., Chen, C.-L., Lv, S.-H., Zhao, Z.-Y., Huang, Y., & Xiang, Y.-Q. (2024). Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study. Oral Oncology, 159, 107074. https://doi.org/10.1016/j.oraloncology.2024.107074

Chicago

He, Shui-Qing, Guo-Ying Liu, Ya-Hui Yu, Lin Wang, Guo-Yi Zhang, Ding-Sheng Peng, Wei-Xin Bei, et al. 2024. “Establishing M1 Subdivision for de Novo Nasopharyngeal Carcinoma Patients Receiving Immuno-Chemotherapy: A Multicenter, Retrospective Cohort Study.” Oral Oncology 159 (December): 107074. doi:10.1016/j.oraloncology.2024.107074.